Vaginal News and Research

RSS

Baylor's new nurse-midwifery program gets initial accreditation

The new nurse-midwifery program of Baylor University Louise Herrington School of Nursing has been given initial accreditation by the Accreditation Commission for Midwifery Education's Board of Review.

15 Feb 2011

Free, confidential home-kit testing for sexually transmitted infections effective with young people

Infectious disease experts at Johns Hopkins say new research clearly shows that screening teens and young adults for sexually transmitted infections may best be achieved by making free, confidential home-kit testing available over the Internet. From a public health standpoint, the project is a clear winner, the experts say.

14 Feb 2011

Protective immunity against HIV can be achieved without presence of virus neutralizing antibodies in the blood

New research shows that protective immunity against HIV can be achieved without the presence of virus neutralizing antibodies in the blood. The study, published by Cell Press in the February issue of the journal Immunity, demonstrates that a vaccine which stimulates production of specific anti-HIV antibodies in the vaginal tissue was sufficient to protect monkeys from exposure to live virus.

11 Feb 2011

Early amniotomy on first time mothers can shorten delivery time by 10%

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that by performing an amniotomy on first time mothers in situations when labor has to be induced, that delivery time can be shortened by more than 10 percent.

10 Feb 2011

Women use less of self-administered analgesic during labor

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.

10 Feb 2011

LESSOnc technique promising new surgical option for certain liver cancers

Surgeons at UC San Diego Health System have identified a new application for "scarless" surgery tools that are normally used for natural orifice translumenal endoscopic surgery (NOTES).

9 Feb 2011

International research team receives AACR award for innovative, meritorious science

The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus for more than 20 years.

8 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Placental colonization by bacteria could lead to preterm birth and other developmental problems

The type of bacteria that colonize the placenta during pregnancy could be associated with preterm birth and other developmental problems in newborns according to research published in the current issue of the online journal mBio-.

28 Jan 2011

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.

11 Jan 2011

MSU researcher believes pregnancy unmasks predispositions to cardiovascular disease

As the rate of preterm delivery rises - accounting for 12.5 percent of all U.S. births - a Michigan State University epidemiologist is using a $3.7 million federal grant to uncover why some mothers who deliver babies early are at an increased risk of developing cardiovascular disease.

11 Jan 2011

Viveve's non-surgical vaginal laxity treatment receives European CE mark

Viveve, Inc., a development stage women's health company, announced today that it has received the European CE (Conformite Europeenne) mark for the use of its Viveve System for the non-surgical treatment of laxity of the vaginal introitus (opening), after childbirth, to improve female sexual function.

7 Jan 2011

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Repros Therapeutics Inc. today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.

28 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA approves Gardasil for prevention of anal cancer

The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

23 Dec 2010

Teen birth rate at a seven decade low: Report

Figures reveal that fewer teenagers are giving birth and the numbers are a seventy year low. Reasons are not specified but two decades of public-health initiatives to curb teenage pregnancy may be paying off feel experts. Report co author Brady Hamilton, a statistician at CDC’s National Center for Health Statistics said, “One of the biggest highlights is the continuing decline in teen births -- down to record lows.”

22 Dec 2010

Water-based lubricants cause fewer genital problems

A new study by sexual health researchers at Indiana University found that women who used lubricant during sex reported significantly higher levels of satisfaction and pleasure.

9 Dec 2010

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

Columbia Laboratories, Inc. and Watson Pharmaceuticals, Inc. today announced positive top-line results from the PREGNANT Study, a large, global Phase III clinical trial evaluating PROCHIEVE® 8% vaginal progesterone gel to reduce the risk of preterm birth in women with a short cervical length as measured by transvaginal ultrasound at mid-pregnancy.

7 Dec 2010

Washington State Hospital Association makes public surgical infection rates

Today, the Washington State Hospital Association is releasing hospital-specific surgical infection rate data. This is the first time this information has been made public.

1 Dec 2010